A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis

Activo, no reclutaClinicalTrials.gov

ID: NCT03992417Tipo: OBSERVATIONALInicio: 11 de jun de 2019Fin estimado: 31 de mar de 2027

Traducción no disponible, mostrando original

Resumen

Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant treatments of AD Secondary Objectives: * To characterize real-world use patterns of Dupixent® for AD (eg, used regimens, reason for initiation of new treatments, concomitant therapies, treatment durations and reasons for discontinuation and/or switching) * To assess the long-term effectiveness of Dupixent® in AD patients in a real-world setting * To assess comorbid atopic conditions and effects of treatment in comorbid atopic conditions in patients who receive Dupixent® for AD * To collect safety data on study participants

Descripción detallada

Participants enrolled in the study will be followed for 5 years.

Elegibilidad

Edad mínima: 12 YearsSexo: ALL

Criterios de inclusión

Male or female, 12 years or older at the baseline visit. Note: Adolescent participants (at least 12 years old, but less than 18 years) are eligible only after Dupixent® receives the respective country's regulatory approval for use in this age group;
Initiating treatment with Dupixent® for AD according to the country-specific prescribing information. Note: Participants may be eligible if they have already initiated treatment with Dupixent® for AD within 6 months before their enrollment in the registry, provided that all core baseline data required (Eczema Area and Severity Index \[EASI\], Scoring of Atopic Dermatitis \[SCORAD\], body surface area \[of AD involvement\] \[BSA\], Patient-Oriented Eczema Measure \[POEM\], and Dermatology Life Quality Index \[DLQI\]) by the registry protocol were captured at the time of initiating Dupixent® treatment and are available for entry in the registry database
Able to understand and complete study-related questionnaires
Provide signed informed consent or parental/legally acceptable representative consent and/or patient assent where applicable

Criterios de exclusión

Participants who have a contraindication to the drug according to the country-specific prescribing information label
Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other co-morbidities that can predictably prevent the participant patient from adequately completing the schedule of visits and assessments
Patients currently participating in any interventional clinical trial which modifies patient care
Prior use of Dupixent® within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Intervenciones

drug

Dupilumab SAR231893 (REGN668)

Pharmaceutical form: solution for injection Route of administration: subcutaneous injection

Ubicaciones

Investigational Site Number : 0320013

Pilar, Buenos Aires, Argentina

Investigational Site Number : 0320012

Rosario, Santa Fe Province, Argentina

Investigational Site Number : 0320011

Ciudad Autonoma Bs As, Argentina

Patrocinadores

PrincipalSanofi

ColaboradorRegeneron Pharmaceuticals

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Prospective Observational Study of Patients Receiving D... | EligiMed